Posted on 11-5-2017

Tampa, FL. October 31, 2017. Ultroid, LLC, Ultroid Marketing Development Corp. & Ultroid Technology (collectively “The Ultroid Group”) refutes all representation made by Michael Cao and Dragon Jade international, Ltd. in the Press Release dated October 3rd, 2017.
The Ultroid Group was notified today that Michael Cao and/or Dragon Jade international, Ltd. released a press release stating the Ultroid Marketing Development Corp. (“UMDC”) and Dragon Jade International, Ltd. (“DJIL”) had entered into a MOU for the sale of UMDC to DJIL.
This announcement or press release is 100% false and misleading.
Michael Cao resigned as an Officer and Director of UMDC on October 25th, 2016 and has no authority under which to represent himself as an Officer or Director of UMDC, beyond that date and is no longer associated with UMDC. Further, Mr. Cao does not have any authority or authorization to bind UMDC in any MOU or contract. Please contact us directly with any questions or concerns.
Ultroid Technologies, Inc. manufactures and markets the Ultroid® Hemorrhoid Management System (“Ultroid® System”). The Ultroid® System, which is FDA cleared and also approved for use in many other nations, is a non-surgical, non-anesthetic, and rapid treatment for hemorrhoid disease (HD).
The Ultroid® System is covered by most major insurers and Medicare, and has been successfully utilized in an estimated 180,000 procedures, by several hundred physicians, practices, clinics, and surgical centers. The Ultroid® procedure has been used in over 150 clinics in the US and was introduced in UK in 2013 where it is currently offered in 15 clinics.

Michael J. Goeree, Chairman, CEO & President
Michael A. Knox, CPA, Director, Exec. VP & CFO
2919 W. Swann Avenue
Suite 106 A
Tampa, FL 33609